2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 45

Small Fiber Neuropathy in Rheumatology Clinics
Abstract Number: 1579

Small Rnaseq Reveals Different Plasma miRNA Signature in Patients with RA and SLE: A Pilot Study
Abstract Number: 3068

Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA
Abstract Number: 2762

Smoking and Severity of Psoriatic Arthritis
Abstract Number: 1775

Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
Abstract Number: 1995

Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis
Abstract Number: 1799

Smoking, Antiphospholipid Antibodies and Thrombosis in SLE
Abstract Number: 3187

Societal Costs and Patients’ Experience of Health Inequities from Psoriatic Arthritis: A Danish Cohort Study
Abstract Number: 3236

Socio-Demographic and Clinical Factors Influencing Generic and Disease-Specific Quality of Life in Patients with Systemic Lupus Erythematosus: Results of a Prospective Multicenter Study
Abstract Number: 1262

Sociodemographic and Clinical Correlates of Physical Therapy Utilization in Adults with Symptomatic Knee Osteoarthritis
Abstract Number: 1252

Socioeconomic Status and Not Race Associated with Delay in Diagnosis and Treatment of Rheumatoid Arthritis
Abstract Number: 124

Socioeconomic-Demographic, Disease Activity, Treatment and Immunologic Variables Affect B Cell Subtypes in Systemic Lupus Erythematosus
Abstract Number: 561

Sodium Intake Is Increased in Patients with Early Rheumatoid Arthritis and Is Associated with Radiographic Erosions
Abstract Number: 17L

Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis
Abstract Number: 1016

Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].